AxoGen (NASDAQ:AXGN) Director Joseph Tyndall Sells 25,108 Shares

AxoGen, Inc. (NASDAQ:AXGN) Director Joseph Tyndall sold 25,108 shares of AxoGen stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $30.98, for a total transaction of $777,845.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

AxoGen Trading Down 2.0%

Shares of AXGN stock traded down $0.60 on Wednesday, reaching $30.01. 679,926 shares of the stock were exchanged, compared to its average volume of 854,756. The company has a quick ratio of 2.64, a current ratio of 4.09 and a debt-to-equity ratio of 0.54. The stock has a market cap of $1.38 billion, a P/E ratio of -600.20 and a beta of 1.06. The firm has a 50 day moving average of $22.57 and a two-hundred day moving average of $16.58. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $34.24.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The firm had revenue of $60.08 million during the quarter, compared to the consensus estimate of $56.90 million. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%. On average, research analysts anticipate that AxoGen, Inc. will post -0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

AXGN has been the topic of several research reports. Canaccord Genuity Group raised their price target on shares of AxoGen from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, December 5th. Raymond James Financial reissued an “outperform” rating and issued a $36.00 price objective on shares of AxoGen in a research report on Thursday, December 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of AxoGen in a research note on Monday. Mizuho began coverage on shares of AxoGen in a research report on Monday, December 1st. They set an “outperform” rating and a $40.00 price target for the company. Finally, Citigroup reiterated a “market outperform” rating on shares of AxoGen in a report on Thursday, October 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.56.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Future Financial Wealth Managment LLC acquired a new stake in AxoGen during the 3rd quarter valued at approximately $27,000. Aquatic Capital Management LLC raised its position in shares of AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of AxoGen during the 3rd quarter valued at approximately $43,000. Tower Research Capital LLC TRC boosted its stake in shares of AxoGen by 189.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after buying an additional 3,327 shares during the last quarter. Finally, AlphaQuest LLC grew its position in shares of AxoGen by 882.2% during the second quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock worth $68,000 after buying an additional 5,637 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.